Eli Lilly and Co. is investing more than $700 million to enhance its global insulin manufacturing capacity in Indianapolis, PR, France and China. During the past year, Lilly has invested more than $1 billion in its manufacturing operations in response to the growing diabetes epidemic and increasing demand for insulin around the world.
 
Approximately half of the total investment will go to improvements at Indianapolis sites, where Lilly has been manufacturing insulin since 1923. In this latest expansion, the company will invest $120 million in France and $350 million in China to enhance insulin cartridge manufacturing capacity, and Indianapolis and PR will receive $245 million to expand insulin-active-ingredient and delivery device manufacturing capacity.
 
“Insulin is a cornerstone of diabetes treatment and its use will only continue to increase given the rising number of people with diabetes around the world,” said Enrique Conterno, senior vice president and president, Lilly Diabetes. “Since introducing the first commercially available insulin 90 years ago, Lilly has helped address the global diabetes burden, and today’s announcement further underscores our deep commitment to diabetes care.”
 
In addition to investments in manufacturing, the company is investing in diabetes research and currently has 14 new molecular entities in clinical development, including three under regulatory review, and another in Phase III, for the treatment of diabetes and related complications.